Beam Therapeutics (NASDAQ:BEAM) Trading Up 9.1% - Here's What Happened

Key Points

• Shares jumped 9.1% on Monday to about $29.93, with roughly 1.63 million shares traded (an 18% decline from average volume).
• Quarterly results beat expectations by a wide margin: Beam reported $2.33 EPS vs. a consensus -$1.13 and revenue of $114.11M vs. an estimate of $13.22M (revenue +280% YoY), though the company still shows negative net margin and analysts forecast a -4.57 FY EPS.
• Analyst sentiment is generally positive but mixed: MarketBeat shows a "Moderate Buy" consensus with an average price target of $49.36, while several firms have recently raised targets (e.g., Wedbush to $65, Bernstein to $41) and others remain neutral or bearish.

Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report)'s stock price was up 9.1% on Monday . The company traded as high as $29.56 and last traded at $29.9280. Approximately 1,628,551 shares traded hands during trading, a decline of 18% from the average daily volume of 1,978,951 shares. The stock had previously closed at $27.43.

Analyst Ratings Changes

A number of analysts have recently weighed in on BEAM shares. Wedbush increased their price objective on Beam Therapeutics from $57.00 to $65.00 and gave the company an "outperform" rating in a research note on Wednesday, February 25th. Weiss Ratings reissued a "sell (d-)" rating on shares of Beam Therapeutics in a research note on Wednesday, January 21st. Sanford C. Bernstein increased their price objective on Beam Therapeutics from $37.00 to $41.00 and gave the company an "outperform" rating in a research note on Tuesday, January 20th. UBS Group started coverage on Beam Therapeutics in a research note on Wednesday, January 7th. They issued a "neutral" rating and a $28.00 price target for the company. Finally, Royal Bank Of Canada raised their price target on Beam Therapeutics from $22.00 to $26.00 and gave the stock a "sector perform" rating in a research note on Wednesday, February 25th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $49.36.

Beam Therapeutics Price Performance

The firm has a market cap of $3.07 billion, a PE ratio of -29.84 and a beta of 2.18. The firm has a 50-day simple moving average of $26.26 and a 200 day simple moving average of $26.48.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last announced its quarterly earnings data on Tuesday, February 24th. The company reported $2.33 EPS for the quarter, beating the consensus estimate of ($1.13) by $3.46. The business had revenue of $114.11 million during the quarter, compared to analyst estimates of $13.22 million. Beam Therapeutics had a negative return on equity of 30.65% and a negative net margin of 57.24%.The company's revenue for the quarter was up 280.3% on a year-over-year basis. During the same quarter last year, the firm posted ($1.09) earnings per share. Sell-side analysts forecast that Beam Therapeutics Inc. will post -4.57 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO John M. Evans sold 30,078 shares of the firm's stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $24.58, for a total transaction of $739,317.24. Following the completion of the transaction, the chief executive officer directly owned 1,047,205 shares in the company, valued at $25,740,298.90. This trade represents a 2.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Amy Simon sold 6,700 shares of the firm's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $24.58, for a total value of $164,686.00. Following the transaction, the insider owned 102,735 shares of the company's stock, valued at $2,525,226.30. The trade was a 6.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 99,544 shares of company stock valued at $2,591,305 over the last ninety days. Insiders own 3.50% of the company's stock.

Hedge Funds Weigh In On Beam Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Purpose Unlimited Inc. bought a new position in shares of Beam Therapeutics during the fourth quarter valued at $80,000. Invesco Ltd. increased its holdings in shares of Beam Therapeutics by 20.5% during the fourth quarter. Invesco Ltd. now owns 213,185 shares of the company's stock valued at $5,909,000 after acquiring an additional 36,321 shares in the last quarter. Axxcess Wealth Management LLC bought a new position in shares of Beam Therapeutics during the fourth quarter valued at $212,000. XTX Topco Ltd bought a new position in shares of Beam Therapeutics during the fourth quarter valued at $426,000. Finally, Virtus Investment Advisers LLC increased its holdings in shares of Beam Therapeutics by 49.0% during the fourth quarter. Virtus Investment Advisers LLC now owns 9,724 shares of the company's stock valued at $270,000 after acquiring an additional 3,200 shares in the last quarter. 99.68% of the stock is currently owned by institutional investors.

About Beam Therapeutics

Beam Therapeutics, Inc NASDAQ: BEAM is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.